Wecare Probiotics announced the successful conclusion of its pivotal seminar, "Clinically Validated + Potency Guaranteed + Officially Registered: Driving Probiotic Products Back to Fundamentals."

Ulcerative colitis (UC) is a lifelong condition marked by painful flares, limited drug options, and a gut microbiota in disarray. This 21-day trial set out to test whether a daily dose of Lactobacillus acidophilus LA85 could deliver measurable relief in the DSS treated mouse model with UC.

​Wecare Probiotics' Bifidobacterium animalis subsp. lactis BLa80 has made history as the first probiotic strain from mainland China to enter the Infant Whitelist with both self-affirmed GRAS and FDA GRAS status.

The global health landscape is undergoing a significant transformation, marked by a dramatic increase in overweight and obesity rates. According to the World Health Organization (WHO), in 2025 this year, a staggering one in eight people worldwide were living with obesity.

Wecare Probiotics announced a landmark strategic partnership with Dassault Systèmes, the world leader in Product Lifecycle Management (PLM) solutions. The official signing ceremony on July 20, 2025, marks a significant milestone in Wecare' journey toward advanced digitalization and sustainable growth.

Wecare Probiotics, as a leading technological innovator, is excited to announce the significant potential of its flagship probiotic strain, Lacticaseibacillus Rhamnosus LRa05, in advancing women's health.